GO
Loading...

ARIAD Pharmaceuticals Inc

More

  • Cramer Interviews Ariad Pharma CEO Monday, 4 Jun 2012 | 10:09 PM ET

    The "Mad Money" host sits down with Harvey Berger to talk prospects and products in the pipeline.

  • Ariad Pharma CEO on Latest Leukemia Data  Monday, 4 Jun 2012 | 6:45 PM ET

    Mad Money host Jim Cramer and Harvey Berger, Ariad Pharmaceuticals chairman/CEO, discuss the state of the health care sector and Ariad's recent research for Sarcoma, Leukemia and other cancers.

  • Stocks to Watch: YHOO, MU & More Wednesday, 11 Apr 2012 | 4:38 PM ET

    Check out which stocks are moving after-the-bell Wednesday:

  • Stocks End Mixed; Nasdaq Hits 11-Year High Wednesday, 21 Mar 2012 | 4:23 PM ET

    Stocks ended narrowly mixed in a lackluster session Wednesday following a weaker-than-expected existing home sales report and as investors were reluctant to jump in following the recent market rally.

  • Futures Turn Narrowly Mixed; Oracle Rallies Wednesday, 21 Mar 2012 | 8:36 AM ET

    U.S. stock index futures hovered around the flatline Wednesday after a pullback in the previous session amid economic outlook worries over China.

  • Stocks to Watch: GIS, ORCL, MRK & More Wednesday, 21 Mar 2012 | 7:55 AM ET

    Take a look at some of Wednesday morning’s early movers:

  • 7 Cancer Drug Stocks to Know Right Now Wednesday, 14 Mar 2012 | 2:39 PM ET
    Three laboratory technicians using microscope

    Savvy investors know that making money on the “ASCO trade” means getting in early as cancer drug stocks typically trade up into the closely watched medical meeting.

  • Cramer makes the call on viewers' favorite stocks.

  • See what's happening, who's talking and what will be making headlines on Monday's Squawk on the Street.

  • The Lightning Round is extended in this CNBC.com exclusive feature.

  • Lightning Round OT: Ariad Pharmaceuticals and Neogen Wednesday, 30 Mar 2011 | 6:58 PM ET

    The Lightning Round is extended in this CNBC.com exclusive feature.

  • Tech vs. Pharma—What's the Best Stock Buy? Monday, 29 Nov 2010 | 11:49 AM ET

    Techs or pharmeceuticals — which is the better buy for investors? Uri Landesman, president of Platinum Partners and Philip Tasho, CEO and CIO at Tamro Capital shared their insights.

  • Top 10 Buy-Rated Stocks Under $5 Friday, 10 Sep 2010 | 1:32 PM ET

    Stocks trading under $5 typically have no analysts' coverage. However, a select few boast of favorable coverage from analysts. The following 10 U.S. stocks trade at less than $5 and have garnered the most "buy" ratings from analysts.  ...A report from TheStreet.

  • ASCO Countdown: Conference Season In Full Bloom Thursday, 15 May 2008 | 12:02 PM ET

    This is gonna be a crazy couple of days. At 9 pm ET tonight the American Society of Clinical Oncology is putting nearly 5,000 studies on its website all at once. Although ASCO says it's all about the science and protecting the "scientific integrity" of its upcoming conference, this is, frankly, an attempt to level the playing field for Wall Street.

  • Audience

    Occasionally -- when the bosses will let me -- I take a day to network, learn and maybe pick up a story idea by attending a biotech or healthcare investment conference. Many firms put on the events for their clients and they often invite reporters to hang out. ... The PR guy told me a couple of sessions during the day would be "closed" to me. It wasn't clear what the closed sessions were all about, and so my curiousity was piqued...

  • Court Rules in Favor of Ariad in Eli Lilly Suit Monday, 9 Jul 2007 | 5:26 PM ET

    Ariad Pharmaceuticals said a U.S. federal court ruled in favor of it and co-complainants in a patent infringement case against Eli Lilly, saying that the patent was valid and enforceable.